Arbutus Biopharma Corporation
ABUS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $11 | $2 | $2 |
| % Growth | -95.1% | 508.8% | 12.1% | – |
| Cost of Goods Sold | $0 | $0 | $9 | $9 |
| Gross Profit | $1 | $11 | -$7 | -$7 |
| % Margin | 97.9% | 100% | -407.9% | -459.7% |
| R&D Expenses | $6 | $5 | $9 | $9 |
| G&A Expenses | $3 | $3 | $6 | $8 |
| SG&A Expenses | $3 | $3 | $6 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $13 | -$11 |
| Operating Expenses | $9 | $9 | $27 | $7 |
| Operating Income | -$8 | $1 | -$35 | -$14 |
| % Margin | -1,567.7% | 13.9% | -1,964.7% | -885.2% |
| Other Income/Exp. Net | $1 | $1 | $10 | $1 |
| Pre-Tax Income | -$8 | $3 | -$25 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | $3 | -$25 | -$13 |
| % Margin | -1,463.5% | 23.5% | -1,390.4% | -796.2% |
| EPS | -0.04 | 0.013 | -0.13 | -0.068 |
| % Growth | -403% | 110.2% | -92.6% | – |
| EPS Diluted | -0.04 | 0.013 | -0.13 | -0.068 |
| Weighted Avg Shares Out | 192 | 192 | 191 | 186 |
| Weighted Avg Shares Out Dil | 192 | 192 | 191 | 190 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | $3 | -$24 | -$15 |
| % Margin | -1,457.1% | 23.9% | -1,369.9% | -974.3% |